Our priorities and lines of work
Séverine LEMOINE, President
Seagen, formerly Seattle Genetics, is a Seattle-based biotechnology company founded in 1998 by scientist Clay Siegall, who continues to lead the company today.
Seagen is dedicated to the field of oncology and our mission is to discover, develop and commercialise high-potential targeted therapies that can change the prognosis and management of cancer patients.
Our focus and strategy has always been to use the most innovative scientific technologies to develop next-generation biotherapies for advanced, difficult-to-treat cancers. To make the fruits of our R&D investments available to professionals and patients even more quickly, we have until now favoured a cooperative model with a strong spirit of partnership.
For the first time, in 2020, Seagen decided to market one of its products under its own name in metastatic breast cancer and has therefore very recently established itself in various European countries with the opening of different subsidiaries, including France where the status of Pharmaceutical Laboratory Operator was obtained in February 2021.
Nicolas RENARD, President
Vertex is an international biotechnology company investing in scientific research to create innovative medicines for patients with serious diseases. In Europe, four Vertex drugs are approved for the treatment of the underlying cause of cystic fibrosis, a rare, multi-systemic, life-threatening disease. The company is also conducting several clinical trials in cystic fibrosis. Vertex's deep understanding of human biology also provides a portfolio of drugs under investigation for other serious diseases such as sickle cell disease, beta thalassaemia, pain, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and APOL1-mediated kidney disease.
Founded in 1989 in Cambridge, Massachusetts, Vertex Pharmaceuticals' global headquarters are now based in Boston's Innovation District, with international headquarters in London. The company now has research and development centres and operating subsidiaries in the United States, Europe, Canada, Australia and Latin America. Vertex Pharmaceuticals is recognised among the best companies in the industry for its quality of work life. Vertex opened its subsidiary in France in 2012.